Vistagen Therapeutics, Inc. (VTGN) stock forecast & analysis
0.3684
NasdaqCM · USD
Up: +0.1170, +46.5%
1 analysis
- Open
- 0.3861
- Previous close
- 0.2514
- Day range
- 0.3351 – 0.5476
- 52-week range
- 0.2000 – 5.14
- Volume (shares)
- 571.85M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 44.38M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.39
- Market cap
- 16.35M
Market Scanner’s AI analysis of Vistagen Therapeutics, Inc. (VTGN), updated September 2026: Vistagen Therapeutics' Fasedienol drug trial results and significant revenue growth contrasted with overbought technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Vistagen Therapeutics, Inc. (VTGN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Vistagen Therapeutics' Fasedienol drug trial results and significant revenue growth contrasted with overbought technical indicators.
Recent analyses for Vistagen Therapeutics (VTGN) covered significant year-over-year quarterly revenue growth of over 500%, driven by developments related to its drug Fasedienol. The company reported positive findings from Phase 3 studies for social anxiety disorder. However, technical indicators suggest the stock may be overextended in the short term, with RSI and MFI readings indicating overbought conditions.
VTGN news & sentiment
News reports highlighted positive developments for Vistagen's Fasedienol drug, including successful trial findings and upcoming presentations. Social media discussions were not covered in the provided notes.
VTGN technical picture
The stock showed strong upward momentum with significant recent price gains, trading well above its 50-day Simple Moving Average. However, momentum indicators signaled overbought conditions, with the price trading above the upper Bollinger Band.
Fundamentals
The company reported substantial year-over-year quarterly revenue growth. However, it also showed significant operational losses with negative earnings per share and operating margins, alongside negative return on equity.
Factors discussed — upside
- Year-over-year quarterly revenue growth of 504.9%
- Positive findings on Fasedienol for social anxiety disorder
- Strong recent upward momentum with significant 7-day and 30-day price changes
- Healthy liquidity with a Current Ratio of 3.066 and Quick Ratio of 2.835
Factors discussed — risks
- Negative EPS and TTM Operating Margin of -904.3%
- Relative Strength Index (RSI) at 77.52, indicating overbought conditions
- Money Flow Index (MFI) at 99.66, indicating intense buying pressure
- Price trading above the upper Bollinger Band
- Revenue growth
- Drug development catalysts
- Technical indicators
- Profitability metrics
Summary updated .
VTGN technical indicators
Common technical indicators for VTGN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.25 | Price above |
| 10-day exponential moving average | 0.26 | Price above |
| Relative strength index (14-day) | 77.52 | Overbought |
| MACD line (12/26/9) | 0.0031 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.19 – 0.31 | Price above the upper band |
Analyses
Recent VTGN.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Vistagen Therapeutics, Inc.?
- Recent analyses highlighted Vistagen Therapeutics' significant year-over-year revenue growth and positive developments for its drug Fasedienol in treating social anxiety disorder. Strong recent price momentum and healthy liquidity were also noted as upside drivers.
- What are the risks for Vistagen Therapeutics, Inc.?
- The analyses pointed to Vistagen Therapeutics' substantial operational losses, indicated by negative EPS and a highly negative TTM Operating Margin. Additionally, technical indicators suggest the stock may be overextended, with readings signaling overbought conditions and intense buying pressure.
- Is Vistagen Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Vistagen Therapeutics, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted Vistagen Therapeutics' significant year-over-year revenue growth and positive developments for its drug Fasedienol in treating social anxiety disorder. Strong recent price momentum and healthy liquidity were also noted as upside drivers. Discussed risks: The analyses pointed to Vistagen Therapeutics' substantial operational losses, indicated by negative EPS and a highly negative TTM Operating Margin. Additionally, technical indicators suggest the stock may be overextended, with readings signaling overbought conditions and intense buying pressure. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Vistagen Therapeutics, Inc.?
- News reports highlighted positive developments for Vistagen's Fasedienol drug, including successful trial findings and upcoming presentations. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Vistagen Therapeutics, Inc.?
- Every analysis of Vistagen Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh VTGN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.